Galcanezumab

Status:
Red
Decision Date:
December 2020
 

Comments

RED1: NICE TA659 - prevention of migraine in adults who have ≥ 4 migraine days per month. See local commissioning algorithm for further details.

CCG commissioned  

Red Drug Classifications

  • 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating

search again

Derby and Derbyshire ICB

Derby and Derbyshire ICB

Please click the button to navigate to our app

Redirect to app